Lakefront Biotherapeutics NV vs PTC Therapeutics
PTC Therapeutics is the larger business, with $1.73bn of revenue in fiscal 2025 against $1.26bn for Lakefront Biotherapeutics NV (1.4 times as much). Lakefront Biotherapeutics NV grew faster (321.6% against 114.5%). PTC Therapeutics kept more of each dollar of sales as profit: a net margin of 39.4% against 28.9%.
| Latest fiscal year | Lakefront Biotherapeutics NVLKFT, 2025 | PTC TherapeuticsPTCT, 2025 |
|---|---|---|
| Revenue | $1.26bn | $1.73bn |
| Revenue growth | 321.6% | 114.5% |
| Net income | $363m | $683m |
| Operating margin | 26.5% | 50.1% |
| Net margin | 28.9% | 39.4% |
| Return on equity | 10.7% | — |
| Free cash flow | −$307m | $702m |
| Cash | $103m | $985m |
| Total debt | $0 | $573m |
| Debt to equity | 0.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | — |
| Market value | $2.11bn | $5.66bn |
| Price vs our value range | — | Above our value range |
| Moat score | — | 11 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 203 sales |